Literature DB >> 7481576

Weight gain associated with neuroleptic medication: a review.

J M Stanton1.   

Abstract

In this article we review the empirical literature on weight gain associated with neuroleptic drug use. Weight gain, which appears to be associated with an increase in appetite, is variable but likely to be larger initially and then plateau. Clozapine and low-potency phenothiazines are associated with the largest gains and molindone with weight loss, but the mechanism is not known. Amantadine and fenfluramine may reverse weight gain to some degree. Dietary fat seems to play an important role in obesity, and research is needed to increase the data base and elucidate possible mechanisms. Studies are also needed to evaluate preventive strategies and to determine which drugs are least likely to produce weight gain as well as which drugs could be added to a neuroleptic regimen to control weight.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7481576     DOI: 10.1093/schbul/21.3.463

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  17 in total

Review 1.  Effects of growth hormone and prolactin on adipose tissue development and function.

Authors:  David J Flint; Nadine Binart; John Kopchick; Paul Kelly
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

Review 2.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

3.  Sleep-disordered breathing: in depression and schizophrenia.

Authors:  Fredric Jaffe; Dimitri Markov; Karl Doghramji
Journal:  Psychiatry (Edgmont)       Date:  2006-07

Review 4.  Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject.

Authors:  Tongeji E Tungaraza
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-31

Review 5.  Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

Authors:  David C Henderson
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.

Authors:  K I Melkersson; A L Hulting; A J Rane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 7.  Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.

Authors:  David C Henderson
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

Review 8.  Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism.

Authors:  K I Melkersson; M-L Dahl; A-L Hulting
Journal:  Psychopharmacology (Berl)       Date:  2004-06-25       Impact factor: 4.530

Review 9.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.

Authors:  Donald P. Hay; Daniel J. Hurley; Hillary C. McGuire; Linda K. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.